Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

CUE

Cue Biopharma Inc

Oct 11 • 04:00PM ET

1.23

Dollar change -0.10
Percentage change -7.52	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI VXF IWC DFAC DFUS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.97	Insider Own	0.92%	Shs Outstand	60.21M	Perf Week	6.03%
Market Cap	74.06M	Forward P/E	-	EPS next Y	-0.52	Insider Trans	0.00%	Shs Float	59.65M	Perf Month	112.07%
Income	-46.96M	PEG	-	EPS next Q	-0.18	Inst Own	28.14%	Short Float	6.37%	Perf Quarter	32.26%
Sales	8.30M	P/S	8.92	EPS this Y	37.16%	Inst Trans	11.45%	Short Ratio	6.49	Perf Half Y	-29.71%
Book/sh	0.44	P/B	2.77	EPS next Y	25.09%	ROA	-81.32%	Short Interest	3.80M	Perf Year	-40.29%
Cash/sh	0.50	P/C	2.47	EPS next 5Y	-	ROE	-138.87%	52W Range	0.45 - 3.25	Perf YTD	-53.41%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.55%	ROI	-181.51%	52W High	-62.14%	Beta	1.94
Dividend TTM	-	Quick Ratio	2.06	Sales past 5Y	163.36%	Gross Margin	58.74%	52W Low	173.33%	ATR (14)	0.18
Dividend Ex-Date	-	Current Ratio	2.06	EPS Y/Y TTM	23.26%	Oper. Margin	-580.34%	RSI (14)	67.02	Volatility	34.80% 20.11%
Employees	53	Debt/Eq	0.52	Sales Y/Y TTM	363.92%	Profit Margin	-566.02%	Recom	1.00	Target Price	3.50
Option/Short	Yes / Yes	LT Debt/Eq	0.20	EPS Q/Q	31.12%	Payout	-	Rel Volume	0.78	Prev Close	1.33
Sales Surprise	106.21%	EPS Surprise	28.57%	Sales Q/Q	92.33%	Earnings	Aug 19 AMC	Avg Volume	585.73K	Price	1.23
SMA20	54.54%	SMA50	69.22%	SMA200	-21.06%	Trades		Volume	464,658	Change	-7.52%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-13-24	Initiated	Jefferies	Buy	$6
Jun-26-23	Resumed	Oppenheimer	Outperform	$10
Nov-21-22	Initiated	Piper Sandler	Overweight	$7
Jan-13-22	Initiated	H.C. Wainwright	Buy	$20
Jan-03-22	Initiated	Craig Hallum	Buy	$28
Nov-24-20	Initiated	Berenberg	Buy	$30
Apr-09-20	Initiated	Stifel	Buy	$21
Jan-28-20	Initiated	BTIG Research	Buy	$26
Jan-22-20	Initiated	JMP Securities	Mkt Outperform	$22

Oct-04-24 09:00AM	Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting (GlobeNewswire) +41.60%
Sep-26-24 11:26PM	Cue Biopharma Announces Pricing of $12.0 Million Public Offering (GlobeNewswire) +49.61%
11:10PM	Cue Biopharma Announces Proposed Public Offering (GlobeNewswire)
Sep-09-24 08:00AM	Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer (GlobeNewswire)
Sep-03-24 08:00AM	Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference (GlobeNewswire) -8.96%
09:36AM	Loading…
Aug-20-24 09:36AM	Q2 2024 Cue Biopharma Inc Earnings Call (Thomson Reuters StreetEvents) +13.68%
Aug-19-24 04:05PM	Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) +11.93%
Aug-14-24 07:45PM	Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-13-24 08:00AM	Cue Biopharma to Host Business Update Call and Webcast (GlobeNewswire)
Jul-26-24 10:13AM	Cue Biopharma downsizes to focus on autoimmune pipeline (Pharmaceutical Technology)
Jul-25-24 04:05PM	Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements (GlobeNewswire)
Jun-04-24 08:00AM	Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting (GlobeNewswire) -5.45%
Jun-03-24 08:00AM	Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024 (GlobeNewswire)
May-30-24 03:30PM	Medical Moonshots: 3 Biotech Stocks Set to Skyrocket (InvestorPlace)
May-09-24 11:54PM	CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -9.14%
04:05PM	Loading…
04:05PM	Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
May-08-24 08:00AM	Cue Biopharma to Present at the 20th Annual PEGS Boston Summit (GlobeNewswire) -12.39%
May-07-24 08:00AM	Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference (GlobeNewswire)
Apr-25-24 09:35AM	Here's Why Cue Biopharma (CUE) is Poised for a Turnaround After Losing -22.83% in 4 Weeks (Zacks)
Apr-24-24 10:01AM	Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -5.33%
Apr-15-24 09:55AM	Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now (Zacks) -8.86%
Apr-09-24 07:36AM	Q4 2023 Cue Biopharma Inc Earnings Call (Thomson Reuters StreetEvents) -6.86%
03:02AM	Cue Biopharma Inc (CUE) Q4 2023 Earnings Call Transcript Highlights: Strategic Alliances and ... (GuruFocus.com)
Apr-08-24 04:05PM	Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights (GlobeNewswire) +10.27%
Apr-02-24 01:53PM	CUE Stock Earnings: Cue Biopharma Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
08:00AM	Cue Biopharma to Host Business Update Call and Webcast (GlobeNewswire)
Feb-29-24 10:00AM	Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium (GlobeNewswire)
Feb-06-24 08:00AM	Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) +5.46%
Dec-14-23 07:04AM	CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023 (InvestorPlace)
Nov-22-23 08:00AM	Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit (GlobeNewswire)
12:55PM	Loading…
Nov-12-23 12:55PM	Cue Biopharma, Inc. (NASDAQ:CUE) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:05PM	Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire) -11.32% +11.33%
Nov-07-23 08:00AM	Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November (GlobeNewswire)
Nov-03-23 12:00PM	Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023 (GlobeNewswire) +10.36%
Nov-02-23 08:00AM	Cue Biopharma to Host Business Update Call and Webcast (GlobeNewswire) +9.90%
Sep-28-23 05:39AM	Acadia (ACAD) Surges 8.3%: Is This an Indication of Further Gains? (Zacks)
Sep-27-23 09:05AM	Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting (GlobeNewswire)
Sep-26-23 08:00AM	Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA® (GlobeNewswire) +5.83%
Aug-10-23 10:37AM	Q2 2023 Cue Biopharma Inc Earnings Call (Thomson Reuters StreetEvents) -13.26%
10:19AM	Cue Biopharma, Inc. (NASDAQ:CUE) Q2 2023 Earnings Call Transcript (Insider Monkey)
08:28AM	Investors in Cue Biopharma (NASDAQ:CUE) have unfortunately lost 83% over the last three years (Simply Wall St.)
Aug-09-23 04:10PM	Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-02-23 08:00AM	Cue Biopharma to Host Business Update Call and Webcast (GlobeNewswire)
Jun-22-23 06:40AM	3 Biotech Stocks to Buy as Companies Ink Major Deals (InvestorPlace)
Jun-14-23 08:00AM	Cue Biopharma to Present at the Federation of Clinical Immunology Societies (FOCIS) 2023 Annual Meeting (GlobeNewswire) -5.03%
Jun-07-23 08:00AM	Cue Biopharma to Host Investor Call (GlobeNewswire)
Jun-05-23 08:00AM	Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference (GlobeNewswire)
May-26-23 06:19AM	3 Biotech Stocks Sitting on Huge-Upside Catalysts (InvestorPlace)
May-25-23 05:00PM	Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-15-23 08:00AM	Cue Biopharma to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-09-23 05:55PM	Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:35PM	Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
May-08-23 08:00AM	Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference (GlobeNewswire)
May-05-23 02:24PM	7 Hot Growth Stocks Poised to Triple in 2023 (InvestorPlace) +6.07%
May-04-23 01:56PM	7 High-Potential Penny Stocks in the Biotech Sector (InvestorPlace)
Apr-25-23 08:00AM	Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors (GlobeNewswire)
Apr-12-23 08:00AM	Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors (GlobeNewswire)
Mar-28-23 10:45AM	2 Strong Buy Penny Stocks With Over 200% Upside on the Horizon (TipRanks) +10.90%
Mar-24-23 07:28AM	Cue Biopharma, Inc. (NASDAQ:CUE) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-22-23 07:37AM	Q4 2022 Cue Biopharma Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-21-23 04:10PM	Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights (GlobeNewswire) +9.39%
Mar-15-23 08:00AM	Cue Biopharma to Host Business Update Call and Webcast (GlobeNewswire) +13.04%
Mar-01-23 08:00AM	Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences (GlobeNewswire)
Feb-22-23 08:00AM	Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401 (GlobeNewswire)
Feb-16-23 10:30AM	Cue Biopharmas Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting (GlobeNewswire)
08:00AM	Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board (GlobeNewswire)
Feb-14-23 05:49AM	Investors in Cue Biopharma (NASDAQ:CUE) have unfortunately lost 81% over the last three years (Simply Wall St.)
Feb-01-23 08:00AM	Cue Biopharma to Present at Two February 2023 Scientific Conferences (GlobeNewswire)
Jan-23-23 08:00AM	Cue Biopharma Announces Chief Medical Officer Transition (GlobeNewswire)
Nov-22-22 08:00AM	Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences (GlobeNewswire)
Nov-17-22 09:00AM	Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE) (ACCESSWIRE) -9.51%
Nov-16-22 05:33AM	Cue Biopharma Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-14-22 04:01PM	Cue Biopharma Reports Third Quarter 2022 Financial Results (GlobeNewswire) +16.31%
08:20AM	Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing (GlobeNewswire)
Nov-10-22 09:00AM	Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire) +6.48%
Nov-09-22 08:00AM	Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November (GlobeNewswire) -11.75%
Nov-07-22 08:00AM	Cue Biopharma to Host Business Update Call and Webcast (GlobeNewswire)
Oct-17-22 12:18PM	Cue Biopharma, Inc. (NASDAQ:CUE) drops to US$91m and insiders who purchased earlier this year lose another US$33k (Simply Wall St.) +6.61%
Oct-05-22 08:00AM	Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire)
Oct-04-22 08:00AM	Cue Biopharma Granted FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (GlobeNewswire) +29.29%
Sep-07-22 08:00AM	Cue Biopharma to Present at Two September 2022 Scientific Conferences (GlobeNewswire) +5.28%
Aug-26-22 06:21AM	Cue Biopharma, Inc. (NASDAQ:CUE) Analysts Just Slashed This Year's Estimates (Simply Wall St.) -5.07%
Aug-23-22 04:30PM	Edited Transcript of CUE.OQ earnings conference call or presentation 23-Aug-22 8:30pm GMT (Thomson Reuters StreetEvents) +5.57% -6.52%
09:55AM	Here's Why Cue Biopharma, Inc. (CUE) Looks Ripe for Bottom Fishing (Zacks)
Aug-22-22 08:00AM	Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms Tumor 1 (WT1) - expressing cancers (GlobeNewswire)
Aug-04-22 04:30PM	Cue Biopharma Reports Second Quarter 2022 Financial Results (GlobeNewswire)
06:35AM	Here's What Cue Biopharma, Inc.'s (NASDAQ:CUE) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Jul-11-22 08:00AM	Cue Biopharma to Present at the Guggenheim I&I Spotlight Series (GlobeNewswire)
Jun-27-22 10:49AM	Shareholders in Cue Biopharma (NASDAQ:CUE) are in the red if they invested a year ago (Simply Wall St.) -5.00%
Jun-13-22 08:00AM	Cue Biopharma to Present at the JMP Securities Life Sciences Conference (GlobeNewswire) -6.25%
Jun-02-22 06:56AM	Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money (Simply Wall St.)
Jun-01-22 08:00AM	Cue Biopharma to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-26-22 05:00PM	Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +7.82%
May-11-22 08:00AM	Cue Biopharma Receives FDA Acceptance of Investigational New Drug (IND) Application for CUE-102 in Wilms Tumor 1 (WT1) - expressing cancers (GlobeNewswire) -15.00%
May-10-22 04:30PM	Cue Biopharma Reports First Quarter 2022 Financial Results (GlobeNewswire)
11:23AM	A Cue Biopharma, Inc. (NASDAQ:CUE) insider increased their holdings by 6.5% last year (Simply Wall St.)
May-06-22 08:25AM	Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-05-22 09:45AM	Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -7.19%
May-04-22 06:25PM	Zymeworks Inc. (ZYME) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-05-22 09:09PM	2 Stocks Under $10 That This Insider Is Aggressively Buying (TipRanks)

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CUE

Cue Biopharma Inc

Upgrade your FINVIZ experience